COMMUNIQUÉS West-GlobeNewswire

Revolo to Present at the 2026 AAAAI Annual Meeting
04/02/2026
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced that it will present a poster on its lead candidate, IRL201104 (‘1104), at the [...]
The Noom Engagement Report: New Data Shows that the GLP-1 Patients Who Use Noom the Most Also Lose the Most Weight and Stay On Medication Program Longest
04/02/2026
Most-engaged members lost 25.2% more weight at week 40 and persisted 2.2x longer on medication program than least-engaged members using the Noom app, demonstrating the benefits of combining GLP-1 medication with Noom’s [...]
SAB BIO to Participate in Upcoming Investor Conferences
04/02/2026
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Balt’s Squid™ Liquid Embolic Receives FDA Approval for Adjunctive Treatment for Patients with Chronic Subdural Hematomas
04/02/2026
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid™ liquid embolic agent. Squid is approved for the [...]
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
04/02/2026
This is the third program that s uccessfully combine s Entera’s oral peptide N- Tab ® platform with OPKO ’s advanced protein chemistry capabilities The c ompanies have accelerated this program and aim to file an [...]
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
Levicept Announces the Appointment of James Sandy as Chief Development Officer
04/02/2026
Leadership Team Strengthened to Support Clinical Development of LEVI-04 for Osteoarthritis SANDWICH, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of [...]
Experience Truly Natural Results: Aesthetics International Leads the Region with Expressive Botox Expertise
04/02/2026
The Era of "Invisible" Enhancements: Aesthetics International Introduces Expressive Botox to Dubai’s Elite Wellness Scene DUBAI, United Arab Emirates, Feb. 04, 2026 (GLOBE NEWSWIRE) -- As Dubai solidifies its reputation [...]
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
04/02/2026
Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage clinical [...]
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
04/02/2026
A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Curium Group today [...]
Novo Nordisk initiates 2026 share repurchase programme
04/02/2026
Bagsværd, Denmark, 4 February 2026 –The execution of Novo Nordisk A/S’ overall share repurchase programme for 2026 of up to DKK 15 billion will be initiated on 4 February 2026. As part of this, Novo Nordisk A/S today [...]
ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury
04/02/2026
Empower BP is a landmark global pivotal study evaluating the safety and effectiveness of the implantable ARC-IM ® System to address blood pressure instability after spinal cord injury (SCI) Blood pressure instability is [...]
Novo Nordisk has published its annual report for 2025
04/02/2026
Bagsværd, Denmark, 4 February 2026 – Today, Novo Nordisk A/S has issued its 2025 annual report. The report is available here: https://www.novonordisk.com/investors/annual-report.html and is attached in iXBRL format. [...]
Michigan Integrative Health Expands Stem Cell Therapy Services to Welcome Canadian Patients
04/02/2026
DETROIT, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Michigan Integrative Health Stem Cells , a leading provider of stem cell therapy and regenerative medicine in Shelby Township, Michigan, announces the expansion of its service [...]
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
04/02/2026
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +8% (cc 1 , +8% USD) with core operating income 1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from priority brands [...]
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
04/02/2026
Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPF Findings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, [...]
Herz P1 Smart Scale: 8-Electrode Body Composition Tracking Device With 56 Metrics — Product Information Updated for 2026
04/02/2026
An informational overview examining dual-frequency BIA technology, segmental body composition analysis, no subscription fee access, and what consumers researching home wellness tracking devices consider when comparing [...]
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
03/02/2026
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry [...]
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
03/02/2026
Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026 GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage [...]

Pages